Deccan Healthcar

Why is Deccan Health Care Ltd falling/rising?

As of 10-Aug, Deccan Health Care Ltd's stock price is at 12.69, down 2.38% and underperforming against the Sensex over various periods. Despite a slight recovery today, the stock shows mixed signals with reduced investor participation and a downward trend overall.

As of 10-Aug, Deccan Health Care Ltd's stock price is currently at 12.69, reflecting a decline of 0.31, or 2.38%. This decrease is part of a broader trend, as the stock has underperformed against the benchmark Sensex over various periods, including a 1-week decline of 2.38% compared to the Sensex's slight drop of 0.12%, and a year-to-date drop of 14.31% against the Sensex's 7.84% decline.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 1.26%, suggesting some positive movement despite the overall decline. However, it is important to note that the stock has experienced three consecutive days of falling prices before today's slight recovery, indicating a potential trend reversal. Additionally, the stock's delivery volume has significantly decreased, with a drop of 90.22% against the 5-day average, which points to falling investor participation and may contribute to the downward pressure on the stock price.<BR><BR>While the stock is trading higher than the 20-day, 50-day, and 100-day moving averages, it remains lower than the 5-day and 200-day moving averages, suggesting mixed signals regarding its short-term and long-term performance. Overall, the combination of recent price declines, reduced investor participation, and underperformance against the benchmark are key factors contributing to the current downward trend in Deccan Health Care Ltd's stock price.

Which are the latest news on Deccan Healthcar?

What does Deccan Healthcar do?

Deccan Health Care Ltd is a micro-cap company specializing in the development, manufacturing, and marketing of healthcare products, including nutraceuticals, cosmeceuticals, and ayurveda products. As of March 2026, it reported net sales of 21 Cr and a market cap of INR 31 Cr.

Overview: <BR>Deccan Health Care Ltd is a micro-cap company in the healthcare services industry, focused on developing, manufacturing, and marketing a diverse range of healthcare products, including nutraceutical, cosmeceutical, and ayurveda products.<BR><BR>History: <BR>Incorporated on August 31, 2017, Deccan Health Care has an operating history of over two decades. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 21 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 31 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.02 <BR>Return on Equity: 2.25% <BR>Price to Book: 0.27 <BR><BR>Contact Details: <BR>Address: 247 2nd Flr Dwarakapuri Colony, Punjagutta Hyderabad Telangana : 500082 <BR>Tel: 91-040-40144508 <BR>Email: investors@deccanhealthcare.co.in <BR>Website: http://www.deccanhealthcare.co.in

How big is Deccan Healthcar?

As of 10th June, Deccan Health Care Ltd has a market capitalization of 31.00 Cr, with recent net sales of 81.91 Cr and a net profit of 2.48 Cr. Shareholder's funds are 106.39 Cr, and total assets amount to 124.93 Cr.

As of 10th June, Deccan Health Care Ltd has a market capitalization of 31.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Deccan Health Care Ltd reported Net Sales of 81.91 Cr and a Net Profit of 2.48 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 106.39 Cr and Total Assets of 124.93 Cr.

Who are in the management team of Deccan Healthcar?

The management team of Deccan Healthcar includes Minto Gupta (Chairman & Managing Director), Meenakshi Gupta (Director), Ruchi Khattar (Independent Director), Kandlakunta Samhitha (Independent Director), and Ravi Ram Prasad (Director).

The management team of Deccan Healthcar includes the following individuals:<BR><BR>1. **Minto Gupta** - Chairman & Managing Director<BR>2. **Meenakshi Gupta** - Director<BR>3. **Ruchi Khattar** - Independent Director<BR>4. **Kandlakunta Samhitha** - Independent Director<BR>5. **Ravi Ram Prasad** - Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Deccan Healthcar?

Deccan Healthcar's peers include Bandaram Pharma, KMS Medisurgi, N G Industries, Samsrita Labs, GKB Ophthalmics, Centenial Surgic, Chennai Meena, Tejnaksh Health., and Sunrest Lifescie. Management risk is below average for several peers, with KMS Medisurgi showing the highest 1-year return at 6.24%, while Deccan Healthcar has the lowest at -41.80%.

Peers: The peers of Deccan Healthcar are Bandaram Pharma, KMS Medisurgi, N G Industries, Samsrita Labs, GKB Ophthalmics, Centenial Surgic, Chennai Meena, Tejnaksh Health., and Sunrest Lifescie.<BR><BR>Quality Snapshot: Below Average management risk is observed at Bandaram Pharma, GKB Ophthalmics, Deccan Healthcar, Centenial Surgic, Tejnaksh Health., and the rest. Average management risk is found at KMS Medisurgi, while Good management risk is noted at N G Industries and Sunrest Lifescie. Growth is rated as Excellent at Sunrest Lifescie, Good at Bandaram Pharma, GKB Ophthalmics, and Deccan Healthcar, while Average growth is seen at KMS Medisurgi and the rest. Below Average growth is present at Centenial Surgic, Tejnaksh Health., and the rest, while Samsrita Labs and Chennai Meena do not qualify. Capital Structure is rated as Good at KMS Medisurgi, N G Industries, GKB Ophthalmics, Deccan Healthcar, and Tejnaksh Health., Average at Centenial Surgic, and Below Average at Bandaram Pharma, while Samsrita Labs and Chennai Meena do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMS Medisurgi at 6.24%, while Deccan Healthcar has the lowest at -41.80%. Deccan Healthcar's return is significantly lower than KMS Medisurgi's. Additionally, the six-month return is negative for Bandaram Pharma, N G Industries, Centenial Surgic, Tejnaksh Health., and Deccan Healthcar.

Should I buy, sell or hold Deccan Health Care Ltd?

Are Deccan Health Care Ltd latest results good or bad?

Deccan Health Care Ltd's latest results are largely negative, showing a 67% drop in net profit despite a 20.64% revenue increase. The significant decline in operating and PAT margins raises concerns about the company's operational efficiency and profitability sustainability.

Deccan Health Care Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q4 FY26, the company reported a net profit of ₹0.33 crore, which is a significant drop of 67% compared to the previous quarter. However, there is a positive year-on-year comparison, with a 175% increase from the same quarter last year.<BR><BR>On the revenue front, Deccan Health Care saw a robust growth of 20.64% quarter-on-quarter, reaching ₹20.98 crore, and a slight increase of 1.11% year-on-year. Despite this revenue growth, the company's operating margin fell sharply from 9.95% in Q3 FY26 to just 4.24% in Q4 FY26, indicating significant operational challenges. The PAT margin also decreased from 5.75% to 1.57%, highlighting pressure on profitability.<BR><BR>Overall, while the revenue growth is encouraging, the drastic decline in net profit and margins suggests that the company is facing serious operational inefficiencies and challenges in maintaining profitability. This disconnect between revenue growth and profit performance raises concerns about the sustainability of its business model. Given these factors, the results can be viewed as unfavorable, particularly for investors focused on profitability and return on equity.

When is the next results date for Deccan Health Care Ltd?

The next results date for Deccan Health Care Ltd is 13 February 2026.

The next results date for Deccan Health Care Ltd is scheduled for 13 February 2026.

How has been the historical performance of Deccan Healthcar?

Deccan Healthcar has experienced fluctuating financial performance, with net sales increasing from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025, but operating profit and cash flow remain negative, indicating ongoing operational challenges. Total assets and liabilities have both risen to INR 124.93 crore by March 2025.

Answer:<BR>The historical performance of Deccan Healthcar shows a fluctuating trend in key financial metrics over the past several years.<BR><BR>Breakdown:<BR>Deccan Healthcar's net sales have shown a consistent increase from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025. However, the total operating income has mirrored this growth, reaching INR 75.06 crore in March 2025. The raw material cost has also risen significantly, from INR 3.98 crore in March 2022 to INR 40.89 crore in March 2025, indicating increased operational expenses. The total expenditure, excluding depreciation, has escalated from INR 27.83 crore in March 2022 to INR 71.91 crore in March 2025. Consequently, the operating profit (PBDIT) has seen a decline from INR 5.34 crore in March 2022 to INR 3.16 crore in March 2025. Profit before tax has also decreased from INR 0.54 crore in March 2022 to INR 1.63 crore in March 2025, while profit after tax has fluctuated, reaching INR 1.16 crore in March 2025, down from INR 0.32 crore in March 2022. The company's total assets have increased from INR 90.63 crore in March 2022 to INR 124.93 crore in March 2025, alongside total liabilities rising from INR 90.63 crore to INR 124.93 crore in the same period. Cash flow from operating activities has remained negative, with a cash flow of -6.00 crore in March 2025, reflecting ongoing challenges in cash generation despite a net cash inflow of 0.00 crore in the same year.

Is Deccan Healthcar overvalued or undervalued?

As of October 6, 2025, Deccan Healthcare's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 42.12, an EV to EBITDA of 13.43, and a low EV to Book Value of 0.41, especially when compared to peers like Sun Pharma and Cipla.

As of 6 October 2025, the valuation grade for Deccan Healthcar has moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its current PE ratio of 42.12, an EV to EBITDA of 13.43, and a notably low EV to Book Value of 0.41. These ratios suggest that the market may not fully recognize the company's potential relative to its earnings and assets.<BR><BR>In comparison to its peers, Deccan Healthcar's valuation stands out; for instance, Sun Pharma has a PE ratio of 34.56 but is considered expensive, while Cipla, also rated attractive, has a significantly lower PE of 22.72. The PEG ratio of Deccan Healthcar is 0.00, which further emphasizes its undervaluation compared to peers like Divi's Lab, which is categorized as very expensive with a PEG of 1.78. Additionally, the company's stock has underperformed against the Sensex over various periods, which may contribute to its current attractive valuation status.

Who are the top shareholders of the Deccan Healthcar?

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta with 14.46%, Focal Ventures Private Limited at 9.69%, and individual investors holding a combined 47.83%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta, who holds the largest stake at 14.46%. Following him, Focal Ventures Private Limited is the highest public shareholder with a 9.69% ownership. Additionally, individual investors collectively hold 47.83% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Deccan Healthcar?

As of May 15, 2025, Deccan Healthcare's trend is mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals, suggesting a cautious outlook.

As of 15 May 2025, the technical trend for Deccan Healthcare has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show a mildly bullish signal. The monthly indicators, including MACD and KST, remain bearish, suggesting underlying weakness. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the mixed signals across different time frames reflect a cautious outlook for the stock.

Has Deccan Healthcar declared dividend?

No Dividend History Available